4:47 PM
 | 
Jan 05, 2018
 |  BioCentury  |  Finance

Watch and wait

Buysiders’ dim views of the big caps heading into 2018

Heading into 2018, buysiders expressed more concerns than optimism about former darlings in the large cap tier.

WBB Securities’ John Nolan, ClearBridge Investments’ Marshall Gordon and AXA Investment Managers’ Linden Thomson are following patent litigation and cardiovascular outcomes data for hypercholesterolemia drug Praluent alirocumab from Regeneron Pharmaceuticals Inc. and Sanofi, but they remain pessimistic on the PCSK9 inhibitor’s commercial prospects.

“While I would like to think outcomes data will help Praluent, I’m not that hopeful that payers will change their restrictions,” said Gordon. “The damage is already done.” The CVOT data are expected this quarter.

In addition, it is not clear when or how patent litigation brought by Amgen Inc. will resolve. In October, the U.S. Court of Appeals for the Federal Circuit tossed out a district court’s injunction blocking U.S. sales of Praluent pending a new trial, which has yet to be scheduled. The suit alleges that Praluent infringes patents for Amgen’s PCSK9 inhibitor, Repatha evolocumab.

Most of the 18 buysiders whom BioCentury interviewed plan to monitor the rollout of CAR Ts from Gilead Sciences Inc. and Novartis AG to see how they manage the complexities of cell processing, logistics, adverse events and...

Read the full 948 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >